Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
Drug results: 2
| doxribtimine | Doxribtimine is approved in combination with doxecitine under the name KYGEVVI. The primary mechanism of action of doxecitine and doxribtimine is the incorporation of nucleosides deoxycytidine (dC) and deoxythymidine (dT) into skeletal muscle mitochondrial deoxyribonucleic acid (DNA) to restore mitochondrial DNA copy number and improve skeletal muscle function in patients with TK2d. Doxecitine and doxribtimine likely utilize residual TK2 activity as well as cytosolic phosphorylation pathways such as thymidine kinase 1 and deoxycytidine kinase to increase mitochondrial DNA precursors deoxycytidine triphosphate and deoxythymidine triphosphate in the mitochondria. |
|
| doxecitine | Doxecitine is approved in combination with doxribtimine under the name KYGEVVI. The primary mechanism of action of doxecitine and doxribtimine is the incorporation of nucleosides deoxycytidine (dC) and deoxythymidine (dT) into skeletal muscle mitochondrial deoxyribonucleic acid (DNA) to restore mitochondrial DNA copy number and improve skeletal muscle function in patients with TK2d. Doxecitine and doxribtimine likely utilize residual TK2 activity as well as cytosolic phosphorylation pathways such as thymidine kinase 1 and deoxycytidine kinase to increase mitochondrial DNA precursors deoxycytidine triphosphate and deoxythymidine triphosphate in the mitochondria. |
|








Citing DrugCentral © 2026.
License